Literature DB >> 31722907

Joel Wohlgemut1.   

Abstract

Year:  2019        PMID： 31722907      PMCID： PMC6853365     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  9 in total

1.  Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.

Authors:  Anuj Shah; Anand Shewale; Corey J Hayes; Bradley C Martin
Journal:  Stroke       Date:  2016-04-21       Impact factor: 7.914

2.  Aligning health care policy with evidence-based medicine: the case for funding direct oral anticoagulants in atrial fibrillation.

Authors:  James A Stone; Karen M Earl; Blair J O'Neill; Mukul Sharma; Thao Huynh; Kori Leblanc; Richard Ward; Philip A Teal; Jafna L Cox
Journal:  Can J Cardiol       Date:  2014-10       Impact factor: 5.223

3.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

4.  Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

Authors:  Jeffrey I Weitz; William Semchuk; Alexander G G Turpie; William D Fisher; Cindy Kong; Antonio Ciaccia; John A Cairns
Journal:  Clin Ther       Date:  2015-10-16       Impact factor: 3.393

5.  Is It Time to Systematically Replace Warfarin With a New Oral Anticoagulant for Higher-Risk Patients With Nonvalvular Atrial Fibrillation?

Authors:  Peter Leong-Sit; Jeffrey S Healey
Journal:  Can J Cardiol       Date:  2016-03-24       Impact factor: 5.223

6.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

7.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.

Authors:  Allan C Skanes; Jeff S Healey; John A Cairns; Paul Dorian; Anne M Gillis; M Sean McMurtry; L Brent Mitchell; Atul Verma; Stanley Nattel
Journal:  Can J Cardiol       Date:  2012 Mar-Apr       Impact factor: 5.223

Review 8.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.

Authors:  Jonathan Ac Sterne; Pritesh N Bodalia; Peter A Bryden; Philippa A Davies; Jose A López-López; George N Okoli; Howard Hz Thom; Deborah M Caldwell; Sofia Dias; Diane Eaton; Julian Pt Higgins; Will Hollingworth; Chris Salisbury; Jelena Savović; Reecha Sofat; Annya Stephens-Boal; Nicky J Welton; Aroon D Hingorani
Journal:  Health Technol Assess       Date:  2017-03       Impact factor: 4.014

9.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman
Journal:  Lancet       Date:  2013-12-04       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.